全文获取类型
收费全文 | 3968篇 |
免费 | 160篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 66篇 |
妇产科学 | 22篇 |
基础医学 | 403篇 |
口腔科学 | 133篇 |
临床医学 | 248篇 |
内科学 | 1103篇 |
皮肤病学 | 55篇 |
神经病学 | 187篇 |
特种医学 | 103篇 |
外科学 | 825篇 |
综合类 | 11篇 |
预防医学 | 113篇 |
眼科学 | 54篇 |
药学 | 353篇 |
中国医学 | 26篇 |
肿瘤学 | 452篇 |
出版年
2023年 | 18篇 |
2022年 | 46篇 |
2021年 | 98篇 |
2020年 | 32篇 |
2019年 | 44篇 |
2018年 | 66篇 |
2017年 | 53篇 |
2016年 | 78篇 |
2015年 | 89篇 |
2014年 | 96篇 |
2013年 | 120篇 |
2012年 | 173篇 |
2011年 | 195篇 |
2010年 | 129篇 |
2009年 | 65篇 |
2008年 | 169篇 |
2007年 | 193篇 |
2006年 | 176篇 |
2005年 | 183篇 |
2004年 | 163篇 |
2003年 | 128篇 |
2002年 | 136篇 |
2001年 | 144篇 |
2000年 | 146篇 |
1999年 | 129篇 |
1998年 | 46篇 |
1997年 | 34篇 |
1996年 | 36篇 |
1995年 | 35篇 |
1994年 | 17篇 |
1993年 | 23篇 |
1992年 | 84篇 |
1991年 | 101篇 |
1990年 | 88篇 |
1989年 | 90篇 |
1988年 | 95篇 |
1987年 | 79篇 |
1986年 | 78篇 |
1985年 | 83篇 |
1984年 | 42篇 |
1983年 | 48篇 |
1982年 | 23篇 |
1981年 | 22篇 |
1980年 | 24篇 |
1979年 | 37篇 |
1978年 | 22篇 |
1977年 | 16篇 |
1973年 | 22篇 |
1970年 | 18篇 |
1969年 | 25篇 |
排序方式: 共有4167条查询结果,搜索用时 31 毫秒
41.
Cerulenin, an inhibitor of protein acylation, selectively attenuates nutrient stimulation of insulin release: a study in rat pancreatic islets 总被引:2,自引:0,他引:2
Yajima H Komatsu M Yamada S Straub SG Kaneko T Sato Y Yamauchi K Hashizume K Sharp GW Aizawa T 《Diabetes》2000,49(5):712-717
Nutrients such as glucose stimulate insulin release from pancreatic beta-cells through both ATP-sensitive K+ channel-independent and -dependent mechanisms, which are most likely interrelated. Although little is known of the molecular basis of ATP-sensitive K+ channel-independent insulinotropic nutrient actions, mediation by cytosolic long-chain acyl-CoA has been implicated. Because protein acylation might be a sequel of cytosolic long-chain acyl-CoA accumulation, we examined if this reaction is engaged in nutrient stimulation of insulin release, using cerulenin, an inhibitor of protein acylation. In isolated rat pancreatic islets, cerulenin inhibited the glucose augmentation of Ca2+-stimulated insulin release evoked by a depolarizing concentration of K+ in the presence of diazoxide and Ca2+-independent insulin release triggered by a combination of forskolin and phorbol ester under stringent Ca2+-free conditions. Cerulenin inhibition of glucose effects was concentration dependent, with a 50% inhibitory concentration (IC50) of 5 microg/ml and complete inhibition at 100 microg/ml. Cerulenin also inhibited augmentation of insulin release by alpha-ketoisocaproate, a mitochondrial fuel. Furthermore, cerulenin abolished augmentation of both Ca2+-stimulated and Ca2+-independent insulin release by 10 micromol/l palmitate, which causes palmitoylation of cellular proteins. In contrast, cerulenin did not attenuate insulin release elicited by nonnutrient secretagogues, such as a depolarizing concentration of K+, activators of protein kinases A and C, and mastoparan. Glucose oxidation, ATP content in islets, and palmitate oxidation were not affected by cerulenin. In conclusion, cerulenin inhibits nutrient augmentation of insulin release with a high selectivity. The finding is consistent with a prominent role of protein acylation in the process of beta-cell nutrient sensing. 相似文献
42.
Diagnostic value of intravesical lidocaine for overactive bladder 总被引:11,自引:0,他引:11
Yokoyama O Komatsu K Kodama K Yotsuyanagi S Niikura S Namiki M 《The Journal of urology》2000,164(2):340-343
PURPOSE: To determine the diagnostic use of intravesical lidocaine, we evaluated its effects on the overactive bladder in patients with brain lesions, spinal lesions, benign prostatic hyperplasia (BPH) and idiopathic overactive bladder. MATERIALS AND METHODS: Cystometry was performed before and 15 minutes after intravesical instillation of 20 ml. 4% lidocaine in 57 patients with an overactive detrusor in the storage phase. RESULTS: The percentage increase in bladder capacity for patients with spinal lesions was 136%, compared to 56%, 29% and 41% for patients with brain lesions, BPH and idiopathic bladder overactivity, respectively (significant difference p <0.01 to 0.05). Of the patients with an increase of 50% or more 55% had brain lesions, 80% spinal lesions, 23% BPH and 31% idiopathic bladder overactivity. The incidence of the disappearance of detrusor contractions in patients with spinal lesions was greater than that in the others. CONCLUSIONS: These results suggest that intravesical instillation of 4% lidocaine is useful for identification of overactive bladder attributable to spinal or other lesions. 相似文献
43.
No Improvement of Adult Height in Non-growth Hormone (GH) Deficient Short
Children with GH Treatment
Toshiaki Tanaka Kenji Fujieda Susumu Yokoya Akira Shimatsu Katsuhiko Tachibana Hiroyuki Tanaka Takakuni Tanizawa Akira Teramoto Toshiro Nagai Yoshikazu Nishi Yukihiro Hasegawa Kunihiko Hanew Keinosuke Fujita Reiko Horikawa Goro Takada Masao Miyashita Tadashi Ohno Kazuo Komatsu 《Clinical Pediatric Endocrinology》2006,15(1):15-21
It is still in doubt whether the standard-dose growth hormone (GH) used in Japan (0.5
IU/kg/week, 0.167 mg/kg/week) for growth hormone deficiency is effective for achieving
significant adult height improvement in non-growth hormone deficient (non-GHD) short
children. We compared the growth of GH-treated non-GHD short children with that of
untreated short children to examine the effect of standard-dose GH treatment on non-GHD
short children. GH treatment with recombinant human growth hormone (rhGH) was started
before the age of 11 yr in 64 boys and 76 girls with non-GHD short stature registered at
the Foundation for Growth Science who have now reached their adult height. In 119
untreated boys and 127 untreated girls whose height standard deviation score (SDS) was
below –2 SD at the age of 6 yr, height growth was followed until 17 yr. Height SDS was
significantly lower before GH treatment in the GH-treated group than at the age of 6 yr in
the untreated group, in both sexes. Adult height and adult height SDS were significantly
greater in the untreated group than in the GH-treated group, in both sexes, although the
change in height SDS did not differ significantly. Height SDS was significantly lower
before GH treatment in the GH-treated group than at the age of 6 yr in the untreated
group, so 57 boys and 57 girls whose height SDS at the age of 6 yr in the untreated group
closely matched the height SDS before GH treatment in the GH-treated group were chosen for
comparison. Height SDS did not differ significantly between the GH-treated group before GH
treatment and the untreated group at the age of 6 yr, nor were there differences between
these subgroups in adult height, adult height SDS, or height SDS change, in either sex.
The effect of GH treatment is reported to be dose-dependent and doses over 0.23 mg/kg/week
are reported to be necessary to improve adult height in non-GHD short children. Currently,
the GH dose is fixed at 0.175 mg/kg/week in Japan, and we expected to find, and indeed
concluded, that ordinary GH treatment in Japanese, non-GHD short children does not improve
adult height. 相似文献
44.
Supplement of ulinastatin on renal function after cardiopulmonary bypass 总被引:14,自引:0,他引:14
Ueki M Yokono S Taie S Nogaya J Komatsu H 《Masui. The Japanese journal of anesthesiology》2000,49(2):163-167
The effects of Miraclid (ulinastatin) on renal tubular function after open thorax surgery under cardiopulmonary bypass were investigated. On the 3rd day after open thorax surgery, which had lasted more than 127 min under cardiopulmonary bypass, the levels of urinary ulinastatin in the Miraclid group and control (without Miraclid) were 170 IU.mg Cr-1 and 95 IU.mg Cr-1, respectively. In the Miraclid group, 300,000 units.day-1 of Miraclid was administrated for three postoperative days. N-acetyl-beta-d-glucosaminidase in urine as a marker of tubular function rose significantly on the seventh postoperative day in the control group but not in patients with Miraclid group. These data suggested that Miraclid 300,000 units.day-1 was needed to protect renal tubular function and more than that dose was needed to prevent the deterioration of renal function after open thorax surgery after cardiopulmonary bypass lasting more than 127 min. 相似文献
45.
Tomohiro Komatsu Makoto Ayaori Harumi Uto-Kondo Katsumi Hayashi Katsumi Tamura Hiroki Sato Makoto Sasaki Takafumi Nishida Shunichi Takiguchi Emi Yakushiji Kazuhiro Nakaya Katsunori Ikewaki 《Journal of atherosclerosis and thrombosis》2022,29(5):775
Aims: Inflammation is involved in various processes of atherosclerosis development. Serum C-reactive protein (CRP) levels, a predictor for cardiovascular risk, are reportedly reduced by statins. However, several studies have demonstrated that CRP is a bystander during atherogenesis. While S100A12 has been focused on as an inflammatory molecule, it remains unclear whether statins affect circulating S100A12 levels. Here, we investigated whether atorvastatin treatment affected S100A12 and which biomarkers were correlated with changes in arterial inflammation. Methods: We performed a prospective, randomized open-labeled trial on whether atorvastatin affected arterial (carotid and thoracic aorta) inflammation using18fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and inflammatory markers. Thirty-one statin-naïve patients with carotid atherosclerotic plaques were randomized to either a group receiving dietary management (n=15) or one receiving atorvastatin (10mg/day,n=16) for 12weeks.18F-FDG-PET/CT and flow-mediated vasodilation (FMD) were performed, the latter to evaluate endothelial function. Results: Atorvastatin, but not the diet-only treatment, significantly reduced LDL-cholesterol (LDL-C, -43%), serum CRP (-37%) and S100A12 levels (-28%) and improved FMD (+38%).18F-FDG-PET/CT demonstrated that atorvastatin, but not the diet-only treatment, significantly reduced accumulation of18F-FDG in the carotid artery and thoracic aorta. A multivariate analysis revealed that reduction in CRP, S100A12, LDL-C, oxidized-LDL, and increase in FMD were significantly associated with reduced arterial inflammation in the thoracic aorta, but not in the carotid artery. Conclusions: Atorvastatin treatment reduced S100A12/CRP levels, and the changes in these circulating markers mirrored the improvement in arterial inflammation. Our observations suggest that S100A12 may be an emerging therapeutic target for atherosclerosis. 相似文献
46.
47.
Therapeutic advances in BIG3‐PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer
下载免费PDF全文
![点击此处可从《Cancer science》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Tetsuro Yoshimaru Masato Komatsu Yasuo Miyoshi Junko Honda Mitsunori Sasa Toyomasa Katagiri 《Cancer science》2015,106(5):550-558
Our previous studies demonstrated that specific inhibition of the BIG3‐PHB2 complex, which is a critical modulator in estrogen (E2) signaling, using ERAP, a dominant negative peptide inhibitor, leads to suppression of E2‐dependent estrogen receptor (ER) alpha activation through the reactivation of the tumor suppressive activity of PHB2. Here, we report that ERAP has significant suppressive effects against synergistic activation caused by the crosstalk between E2 and growth factors associated with intrinsic or acquired resistance to anti‐estrogen tamoxifen in breast cancer cells. Intrinsic PHB2 released from BIG3 by ERAP effectively disrupted each interaction of membrane‐associated ERα and insulin‐like growth factor 1 receptor beta (IGF‐1Rβ), EGFR, PI3K or human epidermal growth factor 2 (HER2) in the presence of E2 and the growth factors IGF or EGF, followed by inhibited the activation of IGF‐1Rβ, EGFR or HER2, and reduced Akt, MAPK and ERα phosphorylation levels, resulting in significant suppression of proliferation of ERα‐positive breast cancer cells in vitro and in vivo. More importantly, combined treatment with ERAP and tamoxifen led to a synergistic suppression of signaling that was activated by crosstalk between E2 and growth factors or HER2 amplification. Taken together, our findings suggest that the specific inhibition of BIG3‐PHB2 is a novel potential therapeutic approach for the treatment of tamoxifen‐resistant breast cancers activated by the crosstalk between E2 and growth factor signaling, especially in premenopausal women. 相似文献
48.
Shigeki Shichijo Kouichi Azuma Nobukazu Komatsu Masaaki Ito Yoshiaki Maeda Yuki Ishihara Kyogo Itoh 《Clinical cancer research》2004,10(17):5828-5836
PURPOSE: The purpose of this work was to provide a scientific basis for specific immunotherapy of colon cancer. EXPERIMENTAL DESIGN: This study focused on identification of colon tumor-associated antigens and HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes (CTLs) generated from tumor-infiltrating lymphocytes of a colon cancer patient. A gene expression cloning method was used to identify genes coding for tumor antigens. Fifty-six peptides with HLA-A2-binding motifs encoded by these proteins were examined for their ability to induce HLA-A2-restricted and tumor-reactive CTLs. RESULTS: We identified the following three genes coding for proliferation-related proteins: thymidylate synthase (TYMS), which is involved in chemoresistance (5-fluorouracil); 5'-aminoimidazole-4-carboxamide-1-beta-d-ribonucleotide transfolmylase/inosinicase (AICRT/I); and phosphoglycerate kinase 1 (PKG1), which was secreted by tumor cells and involved in the angiogenic process. TYMS was preferentially expressed in tumor cells, whereas AICRT/I and PKG1 were equally expressed in both cancer cells and normal tissues at the mRNA level. Among 56 peptides with HLA-A2-binding motifs encoded by these proteins, 8 peptides were recognized by the CTLs, and 5 of 8 peptides were also recognized by the CTL precursors without ex vivo activation in the peripheral blood of colon cancer patients. Furthermore, four of them (one each from TYMS and PKG1 and two from AICRT/1) possessed the ability to induce HLA-A2-restricted and peptide-specific CTLs cytotoxic to colon tumor cells in peripheral blood mononuclear cells of colon cancer patients. CONCLUSIONS: TYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively. 相似文献
49.
Atrazine-induced aromatase expression is SF-1 dependent: implications for endocrine disruption in wildlife and reproductive cancers in humans 总被引:2,自引:0,他引:2
Fan W Yanase T Morinaga H Gondo S Okabe T Nomura M Komatsu T Morohashi K Hayes TB Takayanagi R Nawata H 《Environmental health perspectives》2007,115(5):720-727
BACKGROUND: Atrazine is a potent endocrine disruptor that increases aromatase expression in some human cancer cell lines. The mechanism involves the inhibition of phosphodiesterase and subsequent elevation of cAMP. METHODS: We compared steroidogenic factor 1 (SF-1) expression in atrazine responsive and non-responsive cell lines and transfected SF-1 into nonresponsive cell lines to assess SF-1's role in atrazine-induced aromatase. We used a luciferase reporter driven by the SF-1-dependent aromatase promoter (ArPII) to examine activation of this promoter by atrazine and the related simazine. We mutated the SF-1 binding site to confirm the role of SF-1. We also examined effects of 55 other chemicals. Finally, we examined the ability of atrazine and simazine to bind to SF-1 and enhance SF-1 binding to ArPII. RESULTS: Atrazine-responsive adrenal carcinoma cells (H295R) expressed 54 times more SF-1 than nonresponsive ovarian granulosa KGN cells. Exogenous SF-1 conveyed atrazine-responsiveness to otherwise nonresponsive KGN and NIH/3T3 cells. Atrazine induced binding of SF-1 to chromatin and mutation of the SF-1 binding site in ArPII eliminated SF-1 binding and atrazine-responsiveness in H295R cells. Out of 55 chemicals examined, only atrazine, simazine, and benzopyrene induced luciferase via ArPII. Atrazine bound directly to SF-1, showing that atrazine is a ligand for this "orphan" receptor. CONCLUSION: The current findings are consistent with atrazine's endocrine-disrupting effects in fish, amphibians, and reptiles; the induction of mammary and prostate cancer in laboratory rodents; and correlations between atrazine and similar reproductive cancers in humans. This study highlights the importance of atrazine as a risk factor in endocrine disruption in wildlife and reproductive cancers in laboratory rodents and humans. 相似文献
50.